Want to see IN:EPIGRAL full AI Analyst Report?
Top Page
Epigral Ltd
(EPIGRAL)
Select Model
Select Model
Rating:58Neutral
Price Target:
₹980.00
▼(-15.74% Downside)
Action:Reiterated
Date:10/22/26
The score is held back primarily by weak cash generation (free cash flow turning negative) and a clearly bearish technical setup (below key moving averages with negative MACD). These are partially offset by a stronger balance sheet with low leverage and a reasonable P/E valuation.
Positive Factors
Low Leverage
A materially lower debt burden strengthens financial resilience and reduces interest-related pressure on future earnings. The improved capital structure should give Epigral greater flexibility to sustain operations, manage industry cycles, and allocate capital toward growth.
Negative Factors
Weak Free Cash Flow
Negative free cash flow weakens the quality of reported profits and can reduce internally generated funding for expansion, debt reduction, or shareholder returns. The sharp deterioration also indicates that cash generation may remain sensitive to working-capital or investment demands.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage
A materially lower debt burden strengthens financial resilience and reduces interest-related pressure on future earnings. The improved capital structure should give Epigral greater flexibility to sustain operations, manage industry cycles, and allocate capital toward growth.
Read all positive factors
Epigral Ltd (EPIGRAL) vs. iShares MSCI India ETF (INDA)
Market Cap
₹38.76B
Dividend Yield0.56%
Average Volume (3M)2.03K
Price to Earnings (P/E)14.3
Beta (1Y)1.40
Revenue Growth4.81%
EPS Growth-37.93%
CountryIN
Employees1,135
SectorGeneral
Sector StrengthN/A
IndustryChemicals
Share Statistics
EPS (TTM)62.82
Shares Outstanding43,141,340
10 Day Avg. Volume2,099
30 Day Avg. Volume2,029
Financial Highlights & Ratios
PEG Ratio-1.15
Price to Book (P/B)1.57
Price to Sales (P/S)1.40
P/FCF Ratio-535.43
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)66.9
Revenue Forecast (FY)₹27.83B
Epigral Ltd Business Overview & Revenue Model
Company Description
Epigral Limited operates in the chemical sector, focusing on the production and global distribution of chlor-alkali products and their associated derivatives. Its diverse product range encompasses chlorinated polyvinyl chloride (CPVC) resins, epic...
How the Company Makes Money
EPIGRAL makes money mainly by selling chemical products to business customers (B2B) in the textile manufacturing ecosystem. Its core revenue streams typically include: (1) sales of textile auxiliaries and processing chemicals (e.g., pretreatment, ...
Epigral Ltd Financial Statement Overview
Summary
Income Statement
70
Positive
Balance Sheet
78
Positive
Cash Flow
45
Neutral
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 26.26B | 24.95B | 25.50B | 18.94B | 21.69B | 15.50B |
| Gross Profit | 7.74B | 4.63B | 10.67B | 7.79B | 6.43B | 7.48B |
| EBITDA | 5.88B | 5.50B | 7.11B | 4.77B | 6.81B | 5.01B |
| Net Income | 2.71B | 3.32B | 3.58B | 1.96B | 3.53B | 2.53B |
Balance Sheet | ||||||
| Total Assets | 0.00 | 35.05B | 31.52B | 27.94B | 24.32B | 21.24B |
| Cash, Cash Equivalents and Short-Term Investments | 50.20M | 54.60M | 965.00M | 31.83M | 142.40M | 250.85M |
| Total Debt | 0.00 | 5.72B | 5.93B | 9.64B | 8.79B | 9.93B |
| Total Liabilities | -22.21B | 12.84B | 12.48B | 15.40B | 13.63B | 13.98B |
| Stockholders Equity | 22.21B | 22.21B | 19.05B | 12.54B | 10.69B | 7.26B |
Cash Flow | ||||||
| Free Cash Flow | 316.30M | -65.30M | 2.46B | -7.90M | 2.10B | -1.72B |
| Operating Cash Flow | 2.67B | 3.88B | 4.41B | 3.98B | 6.26B | 2.84B |
| Investing Cash Flow | -1.73B | -3.55B | -2.62B | -4.01B | -4.37B | -4.55B |
| Financing Cash Flow | -980.80M | -457.90M | -1.64B | -75.98M | -2.00B | 1.95B |
Epigral Ltd Technical Analysis
Negative
1163.05
Price Trends
1082.12
Negative
1091.00
Negative
1078.29
Negative
Market Momentum
-49.45
Positive
28.63
Positive
6.02
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:EPIGRAL, the sentiment is Negative. The current price of 1163.05 is above the 20-day moving average (MA) of 980.78, above the 50-day MA of 1082.12, and above the 200-day MA of 1078.29, indicating a bearish trend. The MACD of -49.45 indicates Positive momentum. The RSI at 28.63 is Positive, neither overbought nor oversold. The STOCH value of 6.02 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:EPIGRAL.
Epigral Ltd Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | ₹9.06B | 11.35 | ― | 0.40% | 13.23% | 22.22% | |
60 Neutral | ₹40.68B | 61.27 | ― | 3.19% | 7.07% | ― | |
58 Neutral | ₹38.76B | 14.28 | ― | 0.56% | 4.81% | -37.93% | |
57 Neutral | ₹11.93B | 22.11 | ― | 0.99% | 1.41% | 946.41% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
55 Neutral | ₹34.32B | 12.59 | ― | 2.35% | 8.62% | 20.79% | |
54 Neutral | ₹195.46B | 25.12 | ― | 0.52% | 8.20% | 29.06% |
* General Sector Average
IN:EPIGRAL
Epigral Ltd
898.35
-790.21
-46.80%
IN:DEEPAKNTR
Deepak Nitrite Limited
1,433.05
-310.74
-17.82%
IN:GUJALKALI
Gujarat Alkalies & Chemicals Ltd.
553.90
10.50
1.93%
IN:INDOAMIN
Indo Amines Limited
124.85
-6.42
-4.89%
IN:STYRENIX
Styrenix Performance Materials Ltd
1,951.75
-455.84
-18.93%
IN:VALIANTORG
Valiant Organics Limited
425.50
110.50
35.08%
Epigral Ltd Corporate Events
Epigral to Host Investor and Analyst Plant Visit at Dahej Facility
Oct 21, 2026
Epigral Ltd has announced that Elara Securities (India) Pvt Ltd will conduct an investor and analyst visit to the company’s manufacturing plant in Dahej, Gujarat, on 22 October 2026, with the schedule subject to change based on operational o...
Epigral Files Q1 FY27 Earnings Call Transcript With Exchanges
Jul 30, 2026
Epigral Limited has submitted to the stock exchanges the official transcript of its Q1 FY27 results conference call, held on July 27, 2026, in compliance with disclosure norms under SEBI’s listing regulations. The filing is addressed to both...
Epigral schedules one-on-one meeting with VVD Asset Managers
Jul 30, 2026
Epigral Ltd has notified the stock exchanges that it will hold a one-on-one meeting with VVD Asset Managers in Ahmedabad on Monday, 3 August 2026, as part of its ongoing investor and analyst engagement activities. The company emphasized that only ...
Epigral Denies Role in Surge in Trading Volumes, Cites Market-Driven Factors
Jul 22, 2026
Epigral Ltd has responded to a query from the National Stock Exchange after a significant increase in trading volumes of its shares across exchanges. The company stated that it has already made all required disclosures relating to its operations a...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.